HEPION PHARMACEUTICALS INC (HEPA) Stock Analyst Earnings Estimates
NASDAQ:HEPA - Nasdaq - US4268974015 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 104.07% | N/A 52.99% | N/A 35.94% | ||||||||||||
| EBITDA YoY % growth | -1.67M | -13.94M -734.73% | -20.79M -49.14% | -20.99M -0.96% | -14.57M 30.59% | -7.74M 46.88% | -20.12M -159.95% | -30.31M -50.65% | -43.54M -43.65% | -45.191M -3.79% | -19.316M 57.26% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.67M | -13.96M -735.93% | -20.81M -49.07% | -21.02M -1.01% | -14.59M 30.59% | -7.77M 46.74% | -20.15M -159.33% | -30.4M -50.87% | -43.62M -43.49% | -45.258M -3.76% | -19.347M 57.25% | N/A -330.74% | N/A -10.77% | N/A -96.69% | N/A 29.94% | N/A 24.46% | N/A 62.21% | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 94.77% | -2,530.00 51.22% | N/A 82.26% | -590.00 -31.46% | -616.00 -4.41% | N/A 98.11% | N/A 54.51% | N/A -24.04% | N/A 1.71% | N/A 25.87% | N/A 24.47% | N/A 63.66% | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -2.15 41.45% | % | ||
| Q4 2024 Q2Q % growth | 98.61% | -1.68 | % | |
| Q3 2024 Q2Q % growth | 98.77% | -1.68 | % | |
| Q2 2024 Q2Q % growth | 99.15% | -1.56 | % | |
| Q1 2024 Q2Q % growth | 97.89% | -3.67 | % | |
| Q4 2023 Q2Q % growth | -121.00 6.92% | -134.13 | 13.13 | 9.79% |
| Q3 2023 Q2Q % growth | -137.00 -24.55% | -159.12 | 22.12 | 13.90% |
| Q2 2023 Q2Q % growth | -184.00 29.23% | -169.49 | -14.51 | -8.56% |
| Q1 2023 Q2Q % growth | -174.00 -93.33% | -183.60 | 9.60 | 5.23% |
| Q4 2022 Q2Q % growth | -130.00 -1.96% | -132.60 | 2.60 | 1.96% |
| Q3 2022 Q2Q % growth | -110.00 -56,659.55% | -173.40 | 63.40 | 36.56% |
| Q2 2022 Q2Q % growth | -260.00 -259,900.00% | -122.40 | -137.60 | -112.42% |
| Q1 2022 Q2Q % growth | -90.00 25.00% | -132.60 | 42.60 | 32.13% |
| Q4 2021 Q2Q % growth | -127.50 56.03% | -122.40 | -5.10 | -4.17% |
| Q3 2021 Q2Q % growth | 99.97% | -0.19 | % | |
| Q2 2021 Q2Q % growth | -0.10 99.98% | -0.19 | 0.09 | 48.40% |
| Q1 2021 Q2Q % growth | -120.00 87.63% | -204.00 | 84.00 | 41.18% |
| Q4 2020 Q2Q % growth | -290.00 45.28% | -209.10 | -80.90 | -38.69% |
| Q3 2020 Q2Q % growth | -690.00 -30.19% | -520.20 | -169.80 | -32.64% |
| Q2 2020 Q2Q % growth | -580.00 | -510.00 | -70.00 | -13.73% |
| Q1 2020 Q2Q % growth | -970.00 | -255.00 | -715.00 | -280.39% |
| Q4 2019 Q2Q % growth | -530.00 | -984.30 | 454.30 | 46.15% |
| Q3 2019 Q2Q % growth | -530.00 | -652.80 | 122.80 | 18.81% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |